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Abstract
We aimed to study the effects of hypothetical interventions on systolic blood pressure (SBP) and smoking on risk of stroke 
and dementia using data from 15 years of follow-up in the Rotterdam Study. We used data from 4930 individuals, aged 
55–80 years, with no prior history of stroke, dementia or cognitive impairment, followed for 15 years within the Rotterdam 
Study, a population-based cohort. We defined the following sustained interventions on SBP: (1) maintaining SBP below 
120 mmHg, (2) maintaining SBP below 140 mmHg, (3) reducing SBP by 10% if above 140 mmHg, (4) reducing SBP by 
20% if above 140 mmHg, and a combined intervention of quitting smoking with each of these SBP-lowering strategies. We 
considered incident stroke and incident dementia diagnoses as outcomes. We applied the parametric g-formula to adjust for 
baseline and time-varying confounding. The observed 15-year risk for stroke was 10.7%. Compared to no specified interven-
tion (i.e., the “natural course”), all interventions that involved reducing SBP were associated with a stroke risk reduction of 
about 10% (e.g., reducing SBP by 20% if above 140 mmHg risk ratio: 0.89; 95% CI 0.76, 1). Jointly intervening on SBP and 
smoking status further decreased the risk of stroke (e.g., risk ratio: 0.83; 95% CI 0.71, 0.94). None of the specified interven-
tions were associated with a substantive change in dementia risk. Our study suggests that a joint intervention on SBP and 
smoking cessation during later life may reduce stroke risk, while the potential for reducing dementia risk were not observed.
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Introduction
The increase in life expectancy over the past decades has 
profound implications on the occurrence of diseases. As a 
result of the rapid demographic aging, the burden from com-
mon age-related diseases such as stroke and dementia are 
expected to rise dramatically [1]. As such, effective strate-
gies to prevent or delay the onset of such diseases are in dire 
need. Targeting generally healthy individuals for age-related 
chronic diseases has the potential to have the greatest overall 
impact on population health [2].
High blood pressure is a well-known modifiable risk 
factor for stroke [3]. It is also a proposed risk factor for 
dementia [4], though the specific biological mechanisms are 
heterogenous and less clear [5]. Randomized clinical tri-
als have reported that treatment of hypertension reduces the 
risk of first-ever stroke by 35–40% among elderly patients 
with systolic hypertension [6, 7]. Some observational studies 
have assessed the association between lifestyle factors (i.e. 
unhealthy diet, smoking, drinking and physical inactivity) 
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and stroke risk and have reported that 35–55% of stroke 
events were attributed to lifestyle factors [8–10]. Unlike for 
stroke, the evidence from trials and observational studies 
supporting the effects of lowering blood pressure on demen-
tia risk is limited. Overall such trials did not have dementia 
as the primary outcome, were focused on highly selected 
patient groups and had short follow-up time (e.g., 2–4 years 
of follow-up) [6, 11–18]. In contrast, prior observational 
studies assessing the effect of systolic blood pressure or 
antihypertension medication were conducted in population-
based cohorts with longer follow-up [19, 20]. However, in 
both settings, most studies were not conducted to estimate 
the effect of a sustained treatment strategy with appropri-
ate account for time-varying confounding and attention to 
competing risk of death.
As a several-years-long randomized trial in the general 
population has not been conducted (and may be infeasible), 
decisions today regarding dynamic interventions on blood 
pressure and other lifestyle changes (e.g., quitting smok-
ing) can be empirically informed using observational data 
to emulate a “target trial” [21–25]. Target trial emulation 
requires clear specification of the trial protocol elements 
and, when assessing interventions sustained over time, ana-
lytic methods known as “g-methods” are required to appro-
priately account for time-dependent confounding [26]. Pre-
vious studies have shown how results from observational 
studies can closely align with results from randomized con-
trolled trials when the target trial framework is implemented 
[27, 28]. In this study, we emulate a target trial to estimate 
the sustained effects of several hypothetical interventions on 
systolic blood pressure (SBP) control, including in combi-
nation with an intervention on smoking over follow-up, on 
the risk of first-ever stroke and dementia using data from 
15 years of follow-up in the Rotterdam Study.
Methods
We begin by briefly describing the target trial specifications 
and then how we attempt to emulate the trial using data 
from the Rotterdam Study. A detailed comparison between 
the target trial and the emulation using observational data, 
is provided in the online resource, Table e-1.
Target trial specification
Eligibility criteria:
Individuals 55–80 years old, with no prior history of stroke, 
transient ischemic attack, Parkinson´s Disease, Parkinson-
ism, dementia or cognitive impairment.
Treatment strategies:
Eligible individuals are assigned to one of the following 
sustained strategies, to be followed for the duration of the 
study: (1) maintaining SBP below 120 mmHg, (2) main-
taining SBP below 140 mmHg, (3) reducing SBP by 10% 
if above 140 mmHg, (4) reducing SBP by 20% if above 
140 mmHg. The means for following these strategies are 
not pre-specified (i.e., SBP may be reduced via lifestyle 
or medication interventions); we return to this point in the 
discussion. Given the known health effects of smoking, we 
further considered the intervention of (5) quitting smoking, 
and also four joint interventions combining (5) with (1), (2), 
(3), and (4). We compare all these strategies to the “natural 
course”, which represents no pre-specified treatment strat-
egy. Of note, strategies (1) and (2) align with recent studied 
strategies in a randomized trial [17], while (3) and (4) per-
haps are more achievable in practice.
Outcome recording:
The two primary outcomes of interest are first stroke event 
and dementia diagnosis within 15 years of follow-up, as 
recorded by continuous linkage to medical records and peri-
odic cognitive assessments. Death preceding the outcome 
was treated as a competing event.
Start and end of follow‑up:
Each eligible individual is followed from when they meet 
our eligibility criteria described above. They are followed 
until first stroke event, dementia diagnosis, death, incom-
plete follow-up, or administrative end of follow-up after 
15 years from baseline.
Target trial emulation
Study design and public involvement:
To emulate the described target trial, we used data from 
The Rotterdam Study (RS), a population-based prospective 
cohort study among middle age and elderly persons living 
in the Ommoord district in the city of Rotterdam, the Neth-
erlands. Participants living in the district were invited to 
participate in the cohort between 1990 and 1993. All partici-
pants underwent questionnaire administration, physical and 
clinical examinations, and blood sample collection at base-
line (1990–1993) and at follow-up visits from 1993–1995, 
1997–1999, 2002–2005 [29].
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Eligibility criteria:
Same as specified above. Prior history of stroke, transient 
ischemic attack, Parkinson´s Disease, Parkinsonism and 
dementia were assessed by using home interviews and 
by reviewing medical records, and cognitive impairment 
defined as a Mini Mental State Examination (MMSE) below 
26 at first study visit. Thus, of the 7983 persons who par-
ticipated at baseline, 5193 were considered eligible for this 
study based on the above-mentioned criteria. We further 
required complete information at baseline on SBP, BMI, 
smoking status and hypertensive medication, giving a final 
sample size of 4930 participants (Fig. 1). Participants with 
missing covariates, which represent a 5% of the eligible sam-
ple, were, on average, three years older than those included, 
had a higher frequency of primary education and had a 
higher prevalence of heart disease and diabetes at baseline 
(Online resource, Table e-2).
Treatment strategies:
Same as specified above. SBP was measured in two read-
ings using a random-zero sphygmomanometer in a sitting 
position, and the mean of both measurements was calculated 
during each follow-up visit. Smoking habit for cigarettes was 
collected using a detailed questionnaire and was categorized 
as never, current and former.
Outcome recordings: 
Incident stroke was collected by continuously monitoring 
through computerized linkage of the study database and 
digitized medical records from general practitioners and the 
Regional Institute for Outpatient Mental Health Care. For 
participants who moved outside the study district or lived 
in nursing homes, medical records were regularly checked 
by contacting their treating physicians. Research physicians 
reviewed all potential strokes using hospital discharge letters 
and information from general practitioners and nursing home 
Fig. 1  Flowchart
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physicians. An experienced vascular neurologist verified the 
stroke diagnosis [30, 31]. In accordance with World Health 
Organization criteria, stroke was defined as a syndrome of 
rapidly emerging clinical signs of focal or global disturbance 
of cerebral function. Symptoms should last ≥24 h or cause 
death, with no apparent cause other than of vascular origin.
Dementia diagnosis was collected by screening during the 
cohort visits, using MMSE and the Geriatric Mental Sched-
ule (GMS) organic level. Screen-positives (MMSE < 26 or 
GMS organic level > 0) subsequently underwent an examina-
tion and informant interview with the Cambridge Examina-
tion for Mental Disorders in the Elderly. A consensus panel 
led by a consultant neurologist established the final diagno-
sis according to standard criteria for dementia (DSM-III-R). 
Additionally, participants were continuously followed up for 
the occurrence of dementia through automated linkage of 
general practitioners’ medical records with the study data-
base [32, 33] as with stroke.
Vital status was obtained on a weekly basis via munici-
pal population registries and through general practitioners’ 
and hospitals’ databases. All-cause mortality was defined 
as participants who died from any cause during the total 
follow-up period.
Start and end of follow‑up:
We defined baseline as the date of recruitment in the Rot-
terdam Study for individuals for whom the above-described 
eligibility criteria were met on that date. Study participants 
were followed up from study baseline until stroke, dementia, 
death, censoring due to loss to follow-up, or 15 years after 
baseline, whichever occurred first. We defined loss to follow-
up for stroke as follows: participants who skipped a visit 
or were lost to follow-up were censored at the last year in 
which the next visit could have taken place. Of the included 
participants who did not develop the main outcome or died 
during follow-up, 283 (9%) were lost after the first visit, 408 
(13%) after the second visit, 230 (7%) after the third visit, 
and 2285 (71%) were censored after the fourth round. For 
dementia analyses, we followed participants until dementia 
diagnosis, death, or censored as previously defined. Of the 
4930 included participants, 280 (9%) were lost after the first 
visit, 398 (12%) after the second visit, 194 (6%) after the 
third visit, and 2324 (73%) were censored after the fourth 
round (Fig. 1).
Statistical analysis
To estimate the risk of stroke and dementia under the 
described hypothetical interventions, we used the parametric 
g-formula, an extension of standardization to time-varying 
exposures and confounders. Under the assumptions of no 
unmeasured confounding and no model misspecification, 
this method provides an estimate of the risk of outcomes 
under full adherence to different hypothetical sustained 
interventions [22, 25, 34–36].
The simplified steps for the parametric g-formula using 
stroke as the outcome are described as follows:
1. Fit parametric regression models for each of the time-
varying covariates, as a function of baseline covariates 
and covariates history among participants followed up 
to time k.
2. Fit parametric regression models for stroke and death, 
as a function of baseline covariates and covariates his-
tory among participants followed up to the time k, using 
pooled logistic regression to approximate time-to-failure 
risk.
3. Use a Monte Carlo simulation to generate life histories 
for a pseudo-population of 10,000 simulated individuals.
a. Baseline covariates are randomly sampled with 
replacement from the original population.
b. The values of time-varying covariates are drawn 
from the parametric distribution in Step 1.
c. The value of the covariates that will be “intervened” 
on is set according to the defined strategy (skip this 
step for the “natural course strategy”).
d. The predicted risk of dementia and death is calcu-
lated for each individual in the pseudo-population.
4. Calculate the mean predicted risk of stroke and death at 
15 years in the pseudo-population.
5. Calculate the risk difference between each strategy and 
the natural course.
6. Repeat previous steps in 500 bootstraps samples to 
obtain the 95% confidence interval (CI).
7. For each strategy repeat step 3–6.
The same steps were performed with dementia as an out-
come. Our primary analyses consisted of models with base-
line confounders which included: age with a quadratic term, 
sex, APOE-ε4 carrier, history of type-II diabetes mellitus, 
history of heart disease, education level, baseline SBP with 
a cubic term. Additionally, we also included time-varying 
covariates: the visit process, SBP, cholesterol, BMI, alcohol 
intake, smoking status, hypertensive medication, incident 
heart disease, incident diabetes, incident cancer, incident 
transient ischemic attack and incident Parkinson Disease or 
Parkinsonism. Details on measurements of these variables 
are available in the online supplementary material (Measure-
ments). When stroke was the principal outcome, we included 
dementia as a time-varying confounder, and vice versa. All 
covariates that were measured during the visit process were 
modeled under the condition of having attended the visit 
(Online resource, Table e-3). To probe for potential model 
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misspecification, we estimated the difference between the 
observed mean value and the predicted mean value for each 
covariate (Online resource, Figure e-1, Figure e-2). We also 
conducted a sensitivity analysis of reordering the time-var-
ying covariates to probe potential model misspecification.
The results are presented as the average causal effect 
under each hypothetical intervention at 15 years of follow-up 
compared to the natural course as a risk ratio and risk differ-
ence. For each intervention, we further report the cumulative 
proportion of participants who would have had to have been 
intervened on during the follow-up, to adhere to the strategy. 
We additionally presented the standardized cumulative inci-
dence curves, comparing the risk over time under the natural 
course and the joint treatment strategy.
Competing risk analysis
During follow-up, individuals can die before developing 
stroke and dementia, and interventions may affect the risk 
of death in our main analysis. For this reason, we estimate 
the risk of stroke and dementia taking into account that 
individuals can also progress to death. This means that the 
effect on our main outcome is through all pathways between 
the interventions and the outcome, including those possibly 
mediated by this competing event. We additionally run the 
primary analysis considering death as a censoring event, 
however the interpretation in this setting emulates a coun-
terfactual world in which death could be entirely prevented, 
which would not be realistic and relies on additional stronger 
no-unmeasured-confounding assumptions [37]. Finally, we 
performed analysis considering the effect of each interven-
tion in the composite outcome with death (i.e., stroke and 
death, dementia and death).
Subgroup analysis
We repeated our primary analyses within the following sub-
groups: age between 55 and 65 years; age between 66 and 
80 years; women, men; without hypertensive medication at 
baseline; and free of heart disease at baseline.
All g-formula analyses were conducted using SAS 9.4 
software and the GFORMULA macro that is publicly avail-
able at http://www.hsph.harva rd.edu/causa l/softw are. The 
SAS code for the GFORMULA macro call for our primary 
analysis is available on the following repository https ://githu 
b.com/palol ili23 /ht_trial _gform ula.
Results
Table 1 shows the baseline characteristics of the study par-
ticipants. The mean age of the participants was 66 years 
and 57% were women. The mean SBP at baseline was 
137 mmHg, and 24% were current cigarette smokers.
Stroke risk
During the 15 years of follow-up, there were 490 cases of 
incident stroke and 1234 deaths. The observed 15 years 
risk for stroke was 10.3% and under the simulated natural 
course was 10.3% (95%CI 9.3, 11.5). The risk of stroke 
under the different hypothetical treatment strategies are 
presented in Table 2. Overall, all interventions that low-
ered SBP under a threshold reduced the risk of stroke by 
approximately 10% compared to the natural course dur-
ing the study period. Although all interventions on SBP 
had a similar association with risk of stroke, the most 
Table 1  Characteristics of cohort at baseline (n = 4930)
MMSE Mini Mental State Examination, BMI body mass index, HDL 
high density lipoproteins
Overall
Female, n (%) 2824 (57.3)
Age, mean (SD) (years) 66.2 (6.6)
Apoe4 carrier, n (%)
    Not carrier 3388 (68.7)
    Carrier 1322 (26.8)
    Missing 220 (4.5)
Education level, n (%)
    Primary 2378 (48.6)
    Further 2044 (41.8)
    Higher 472 (9.6)
MMSE, mean (SD) 28.2 (1.2)
BMI, mean (SD) (kg/m2) 26.3 (3.6)
Cigarette smoking, n (%)
    Never 1551 (31.5)
    Former 2193 (44.5)
    Current 1186 (24.1)
Alcohol intake, mean (SD) (g/day) 10.7 (15.3)
Systolic blood pressure, mean (SD) (mmHg) 137.3 (21.5)
Total cholesterol, mean (SD) (mmol/dl) 6.7 (1.2)
HDL, mean (SD) (mmol/dl) 1.4 (0.4)
Prevalent hypertension, n (%) 2789 (56.6)
Hypertension medication, n (%) 1360 (27.6)
Prevalent heart disease, n (%) 368 (7.7)
Prevalent cancer, n (%) 20 (0.4)
Prevalent diabetes, n (%) 432 (12.9)
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intensive treatment strategy studied (“maintaining SBP 
below 120 mmHg”) required intervening in 98% of the 
population at some point in follow-up, which involved 15% 
more people compared to all other strategies. By contrast, 
smoking cessation was associated with a reduction in 
stroke risk by 7% (RR 95%CI 0.89, 0.97) compared to the 
natural course, and required an intervention on only 26% 
of the population. All joint interventions showed a larger 
reduction in the risk of stroke. For example, lowering SBP 
by 20% if above 140 mmHg and quitting smoking was 
associated with a 17% (RR 95% CI 0.71, 0.94) reduction 
in the risk of stroke over the study period compared to the 
natural course as observed in Fig. 2A. 
Dementia risk
During the 15 years of follow-up, there were 431 cases of 
dementia and 1303 deaths. The observed 15-year risk for 
dementia was 8.9% and under the simulated natural course 
was 9.2% (95% CI 8.2, 10.3%). The risk of dementia under 
the different hypothetical interventions are shown in Table 3. 
Overall, none of the treatment strategies involving SBP 
were associated with substantial changes in risk of demen-
tia. For example, the treatment strategy “maintaining SBP 
below 120 mmHg” was associated with a 6% (RR 95% CI 
0.90, 1.24) increase in dementia risk compared to the natu-
ral course. This pattern was likewise seen for the treatment 
Table 2  Risk of stroke at 15 years of follow-up under natural course and hypothetical interventions
Estimates were based using the parametric g-formula with fixed covariates: age, sex, education, systolic blood pressure, history of diabetes and 
history of heart disease at baseline; and time-varying covariates: visit process, smoking status, systolic blood pressure, body mass index, hyper-
tension medication, total cholesterol and diagnosis of diabetes, heart disease, Parkinson disease, Parkinsonism, transient ischemic attack, demen-
tia or cancer
SBP: Systolic blood pressure (mmHg)
No. Intervention Absolute risk (95% CI) Risk ratio (95% CI) Risk difference (95% CI) Total 
intervened 
(%)
0 Natural course 10.3 (9.3, 11.5) - - 0.00
1 Maintaining SBP below 120 mmHg 9.0 (7.5, 10.7) 0.87 (0.74, 1.02) −1.3 (−2.8, 0.2) 97.8
2 Maintaining SBP below 140 mmHg 9.3 (8.2, 10.6) 0.90 (0.83, 0.98) −1.0 (−1.8, −0.2) 83.5
3 Reducing SBP by 10% if above 140 mmHg 9.3 (8, 10.6) 0.90 (0.80, 0.98) −1.1 (−2.1, −0.2) 82.7
4 Reducing SBP by 20% if above 140 mmHg 9.2 (7.8, 10.6) 0.89 (0.76, 1.00) −1.1 (−2.5, 0.0) 82.7
5 Quitting smoking 9.6 (8.6, 10.8) 0.93 (0.89, 0.97) −0.7 (−1.2, −0.3) 25.9
6 Joint 1 + 5 8.3 (6.9, 10.0) 0.81 (0.68, 0.95) −2.0 (−3.4, −0.5) 98.7
7 Joint 2 + 5 8.8 (7.6, 9.9) 0.85 (0.76, 0.92) −1.6 (−2.6, −0.8) 88.6
8 Joint 3 + 5 8.6 (7.4, 9.8) 0.83 (0.74, 0.92) −1.7 (−2.8, −0.8) 88.2
9 Joint 4 + 5 8.5 (7.2, 9.9) 0.83 (0.71, 0.94) −1.8 (−3.1, −0.6) 88.2
Fig. 2  Risk of stroke and 
death under the natural course 
and under the joint intervention: 
Reduce SBP by 20% if above 
140 mmHg and quit smoking at 
15 years of follow-up
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strategy of smoking cessation and joint treatment strategies 
involving lowering SBP and smoking cessation. For exam-
ple, lowering SBP by 20% if above 140 mmHg and quit 
smoking was associated with an increment in dementia risk 
of 5% (RR 95% CI 0.92, 1.20) as observed in Fig. 3A.
Alternative analyses for competing event
Given that death was modeled as a competing event for both 
outcomes (stroke and dementia), we present the effect of 
the intervention “lowering 20% of SBP if above 140 mmHg 
and quit smoking” on the risk of death in Figs. 2B and  3B 
respectively. Treating death as a censoring event and as 
part of a composite outcome did not meaningfully change 
the conclusions, as presented in the online resource, Table 
e-4, e-5, e-12 e-13.
Subgroup analyses
Table 4 provides estimates for the treatment strategy “low-
ering 20% of SBP if above 140 mmHg and quit smoking” 
on the risk of stroke and dementia by subgroups (age, sex, 
without hypertension medication at baseline, free of heart 
disease at baseline) compared to the natural course. Esti-
mates were relatively consistent for stroke risk across sub-
groups, with the exception of individuals with age below 
Table 3  Risk of dementia at 15 years of follow-up under natural course and hypothetical interventions
Estimates were based using the parametric g-formula with fixed covariates: age, sex, education, systolic blood pressure, history of diabetes and 
history of heart disease at baseline; and time-varying covariates: visit process, smoking status, systolic blood pressure, body mass index, hyper-
tension medication, total cholesterol and diagnosis of diabetes, heart disease, Parkinson disease, Parkinsonism, transient ischemic attack, demen-
tia or cancer
SBP systolic blood pressure (mmHg)
No. Intervention Absolute risk (95% CI) Risk ratio (95% CI) Risk difference (95% CI) Total 
intervened 
(%)
0 Natural course 9.2 (8.2, 10.3) - - 0.0
1 Maintaining SBP below 120 mmHg 9.7 (8, 11.9) 1.06 (0.90, 1.24) 0.6 (−0.9, 2.2) 98.2
2 Maintaining SBP below 140 mmHg 9.2 (8, 10.7) 1.01 (0.92, 1.09) 0.1 (−0.7, 0.8) 83.0
3 Reducing SBP by 10% if above 140 mmHg 9.2 (8, 10.9) 1.01 (0.92, 1.11) 0.0 (−0.8, 1.0) 83.3
4 Reducing SBP by 20% if above 140 mmHg 9.5 (8, 11.4) 1.04 (0.91, 1.18) 0.3 (−0.8, 1.7) 83.3
5 Quitting smoking 9.3 (8.4, 10.6) 1.01 (0.98, 1.06) 0.1 (−0.2, 0.5) 25.9
6 Joint 1 + 5 9.9 (8, 12.2) 1.08 (0.92, 1.26) 0.8 (−0.8, 2.4) 98.8
7 Joint 2 + 5 9.3 (8.1, 10.9) 1.02 (0.93, 1.12) 0.2 (−0.6, 1.1) 88.2
8 Joint 3 + 5 9.3 (8, 11.1) 1.02 (0.93, 1.14) 0.2 (−0.7, 1.3) 88.6
9 Joint 4 + 5 9.6 (8, 11.6) 1.05 (0.92, 1.20) 0.4 (−0.7, 2.0) 88.6
Fig. 3  Risk of dementia and 
death under the natural course 
and under the joint intervention: 
Reduce SBP by 20% if above 
140 mmHg and quit smoking at 
15 years of follow-up
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65 years among whom there appeared to be a much stronger 
association (RR: 0.75, 95% CI 0.56, 0.98).For dementia risk, 
subgroup analyses present similar findings. Additional treat-
ment strategies are presented in the online resource, Table 
e-6 to e- 11, e-14 to e-19.
Discussion
Our study suggests that intervening on blood pressure could 
reduce stroke risk by approximately 10% over 15 years of 
follow-up in a population-based setting, and that combining 
such interventions with smoking cessation could result in an 
overall reduction of 18%. In contrast, our study is consistent 
with these same interventions having null or opposite effects 
on risk of dementia, taking into account that these estimates 
could be affected by how the interventions may decrease the 
risk of death.
Our results on stroke risk are comparable in direction but 
not quite in magnitude of prior studies’ effect estimates. A 
previous meta-analysis of randomized trials has shown that 
a 10 mmHg reduction in blood pressure decreases the risk 
of stroke by 27%, though this effect was observed in a high-
risk population of individuals with cardiovascular diseases 
[38]. The most comparable observational study to ours was 
one emulating hypothetical treatment strategies to reduce 
SBP in middle-aged (i.e., baseline mean age 46.1 years or 
about 20 years younger that our study) healthy individuals 
from Norway, also using the g-formula. This study showed 
that a 23 mmHg average reduction in blood pressure of 
120 mmHg and above resulted in a 45% reduction in stroke 
risk over a 15 year period [35]. The difference in the risk 
estimates might be due to differences in the average age of 
the study populations. Of note, no differences in propor-
tional risk reductions were reported in trials involving per-
sons with systolic blood pressure < 130 mmHg and those at 
high risk (≥160 mmHg) [38]. Our study also adds to these 
prior studies by considering a joint intervention with smok-
ing cessation, although our combined strategies appears 
to reduce stroke risk by a much lower amount (18%) than 
those reported previously in observational studies (35–55%) 
[8–10].
To compare the results from our hypothetical intervention 
on blood pressure (dropping below 120 or 140 mmHg over 
Table 4  Subgroup analyses comparing the joint intervention of reducing SBP by 20% if above 140mmHg and quitting smoking to the natural 
course
SBP systolic blood pressure (mmHg)
Estimates were based using the parametric g-formula with fixed covariates: age, sex, education, systolic blood pressure, history of diabetes and 
history of heart disease at baseline; and time-varying covariates: visit process, smoking status, systolic blood pressure, body mass index, hyper-
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time) in dementia risk with previous research, we must con-
sider the differences in the eligibility criteria, treatment strat-
egies and analytical choices. Our target trial by design fol-
lows similar treatment strategies such as the Systolic Blood 
Pressure Intervention Trial (SPRINT) MIND trial, however 
this trial considered eligible individuals as those who had 
risk of cardiovascular disease [17], which represents a small 
subgroup of our population-based cohort. (Specifically, at 
most 290 individuals in the Rotterdam Study would meet 
criteria at baseline, based on our assessments of SBP, pres-
ence of cardiovascular disease other than stroke and history 
of diabetes.) Similarly, since previous trials were primarily 
designed to assess the effect of antihypertensive medica-
tion on the risk of stroke and did not have dementia as their 
primary outcome, they were tailored to a specific subgroup 
of individuals who required treatment. Eligibility criteria in 
other trials included having had a history of stroke, being 
above 80 years old and having a SBP above 160 mmHg [6, 
11–18]. Furthermore, assessing the comparability of our 
findings with prior observational studies requires caution. 
A recent meta-analysis by Ding et al. studied the effect of 
taking any antihypertensive medication and specific antihy-
pertensive medications and the risk of dementia stratified 
by SBP including five large population-based cohort [19]. 
However, they studied prevalent treatment use at baseline 
and only included baseline covariates for adjustment. Simi-
larly, Walkert al. stratified individuals by longitudinal blood 
pressure patterns (mid-life and late-life normotension/hyper-
tension), but covariates were measured during two of the 
six visits [39]. In contrast, we assessed the sustained effect 
of lowering SBP over time given time-updated covariates. 
Last, we consider that our findings reflect the relevance of 
the competing event of death by other causes, and how esti-
mates are likely affected by the effect of interventions on the 
risk of death, and give a more comprehensive view of the 
implications of these results. This will be especially impor-
tant when we stratify by characteristics that have a different 
survival distribution, as we observe in the different direc-
tion of the effects among women vs. men [40]. Reconsider-
ing these points as part of how we frame research question 
and analytical decisions when using observational data will 
have a direct impact on results interpretation and clinical 
translation.
By leveraging a rich dataset in a population-based 
observational study, high-quality and frequent assess-
ments of outcomes and key covariates, and the use of the 
parametric g-formula to account for the complex con-
founding structure assumed, we emulated a “target trial” 
that may be of key public health interest but would not 
be easily conducted as a randomized trial. However, like 
any observational data analysis, several assumptions need 
to be carefully weighed. The possibility of unmeasured 
confounding remains, and in particular we were unable 
to adjust for covariates such as types of antihypertension 
medications, LDL (as separate from total cholesterol), 
glucose and frailty in our analysis. Likewise, we used 
MMSE as a screening tool and excluded individuals with 
Parkinson disease or Parkinsonism symptoms at baseline, 
but it is possible that persons with subclinical cognitive 
impairment might be included in our analysis at baseline 
or during follow-up [41]. Self-reported smoking status is 
also subject to measurement error, although we did assess 
the consistency of our measurements over time. In addi-
tion, the parametric g-formula relies on several strong 
modeling assumptions. As reported in the online resource 
Figure e-1, Figure e-2, we observed an agreement between 
the mean estimated values of each variable (outcomes and 
covariates) under the natural course with their observed 
values, which supports but does not prove these model 
specifications hold [22]. Furthermore, we did not assess 
the effect of the hypothetical interventions in the specific 
clinical phenotypes of each disease, since numbers on the 
disaggregated clinical subtypes are small and is further 
complicated by each subtype being a competing event for 
each other.
Finally, another key point to reflect upon in interpreting 
our specified treatment strategies is that we did not, in fact, 
specify how SBP would be lowered. This means our esti-
mates are based on the consistency assumption that lower-
ing SBP through any available means (e.g., dietary changes, 
medication use, other lifestyle changes) would have the same 
effect on stroke or dementia risk, or otherwise are at best 
interpretable as estimates for an effect of a weighted aver-
age of several SBP-lowering strategies with weights deter-
mined by the frequency that the particular strategies occur 
in our specific population [42, 43]. Future studies that have 
more detailed assessments of these various SBP-lowering 
treatments are needed to disentangle treatment variation rel-
evance and build upon this initial study. Furthermore, smok-
ing cessation is one of several more specific behavioral inter-
ventions that could be assessed, as well as other metabolic 
factors described in current guidelines [3, 4]. Implementing 
the target-trial framework and defining research questions to 
study more refined or further specified treatment strategies 
is a crucial next step. Doing so will require rich, longitudi-
nal data on the specific interventions under study; the level 
of specificity in the research questions that can be studied 
is hampered in part by the data currently available. Thus, 
while there are certainly limitations in terms of ambiguity 
to the interventions studied in the current paper, they repre-
sent an improvement (in terms of clarity and for informing 
decision-making) over etiologic studies that address SBP’s 
effects with a simplified version of the complexity of real 
data, and a step toward the types of interventions we may 
consider in practice.
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Given previous considerations, studying population-level 
interventions as done here is particularly suitable for pub-
lic health research, in that we can better understand how 
particular recommendations may affect stroke or dementia 
risk at the population-level rather than as estimated in high-
risk subpopulations. Importantly, while the possible effect 
of blood pressure control on dementia risk remains debated, 
our findings nonetheless align with the recent WHO Report’s 
recommendation that lowering blood pressure has substan-
tial benefits (in terms of stroke risk and mortality, here) that 
may motivate blood pressure control regardless of its pos-
sible effects on dementia risk [44].
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